No improvement in Hb levels, as well as other hemolytic parameters, including reticulocyte count, LDH, AST, and TB, in β-Thal-S and α-Thal-NS patients receiving VitE were identified at the end of the intervention. This evidence concerns the gene GSTM1 and tuberculosis.